Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.
致力于开发神经退行性疾病改良疗法的生物技术公司Alterity Therapeutics（（澳大利亚证券交易所股票代码：ATH，纳斯达克股票代码：ATH）（“Alterity” 或 “公司”）今天宣布，独立数据监测委员会（DMC）已完成对试验数据的第三次审查，并建议按计划继续进行 ATH434-201 二期研究。ATH434-201 临床试验是一项针对早期多系统萎缩 (MSA) 患者的 ATH434 的随机、双盲、安慰剂对照研究，这是一种罕见的神经退行性疾病，没有获得批准的减缓或停止其进展的治疗方法。